Prescription medications: A modifiable contributor to obesity

Southern Medical Journal

Volumn 92, Issue 9, 1999, Pages 898-904

  Cheskin, Lawrence J ^a,b   Bartlett, Susan J ^a   Zayas, Roberto ^a   Twilley, Charles H ^a   Allison, David B ^a   Contoreggi, Carlo ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LITHIUM; NEUROLEPTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CASE REPORT; DIETARY INTAKE; DRUG RESPONSE; FEMALE; HUMAN; MALE; OBESITY; PATIENT COMPLIANCE; PRESCRIPTION; WEIGHT GAIN;

EID: 0032831731     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199909000-00009     Document Type: Article

References (44)

1. Centers for Disease Control and Prevention: Update: prevalence of overweight among children, adolescents, and adults, United States, 1988-1994. MMWR 1997; 46(RR-9):199-202
2. Troiano RP, Frongillo EA, Sobal J, et al: The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies. Int J Obes 1996; 20:63-75
3. Flegel KM, Troiano RP, Pamuk ER, et al: The influence of smoking cessation on the prevalence of overweight in the United States. N Engl J Med 1995; 333:1165-1170
4. Kral JG, Heymsfield S: Morbid obesity: definitions, epidemiology, and methodological problems. Gastroenterol Clin North Am 1987; 16:197-205
5. Weiser M, Frishman WH, Michaelson MD, et al: The pharmacologic approach to the treatment of obesity. J Clin Pharmacol 1997; 37:453-473
6. Rossner S, Taylor CL, Byington RP, et al: Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ 1990; 300:902-903
7. Yki-Jarvinen H, Kauppila M, Kujansuu E, et al: Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327:1426-1433
8. Hermann LS, Schersten B, Bitzen PO, et al: Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care 1994; 17:1100-1109
9. Laube H, Linn T, Heyen P: The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 1998; 106:231-233
10. Lee A, Morley JE: Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998; 6:47-53
11. Paolisso G, Amato L, Eccellente R, et al: Effect of metformin on food intake in obese subjects. Eur J Clin Invest 1998; 28:441-446
12. Noury J, Nandeull A: Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDDM. Diabetes Metab 1991; 17:209-212
13. Stoa-Birketvedt G: Effect of cimetidine suspension on appetite and weight in overweight subjects. BMJ 1993; 306:1091-1093
14. Stoa-Birketvedt G, Lovhaug N, Vonen B, et al: H2-receptor antagonist reduces food intake and weight gain in rats by non-gastric secretory mechanisms. Acta Physiol Scand 1997; 161:489-494
15. Garland EJ, Remick RA, Zis AP: Weight gain with antidepressants and lithium. J Clin Psychopharmacol 1988; 8:323-330
16. Szarek BL, Brandt DM: A comparison of weight changes with fluoxetine, desipramine, and amitriptyline: a retrospective study of psychiatric inpatients. J Nerv Ment Dis 1993; 181:702-704
17. Cohen GL: Protriptyline, chronic tension-type headaches, and weight loss in women. Headache 1997; 37:433-436
18. Goldberg SC, Halmi KA, Eckert ED, et al: Cyproheptadine8in anorexia nervosa. Br J Psychiatry 1979; 134:67-70
19. Rahman KM: Appetite stimulation and weight gain with cyproheptadine (periactin) in tuberculosis patients (double-blind clinical study). Med J Malaysia 1975; 29:270-274
20. Brucra E: Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 1992; 49(suppl 2):35-42
21. Chen Y, Silverstone T: Lithium and weight gain. Int Clin Psychopharmacol 1990; 5:217-225
22. Greil W, Wetterling T, Tegeler J, et al: Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord 1997; 43:151-161
23. Masters JC: When lithium does not help: the use of anti-convulsants and calcium channel blockers in the treatment of bipolar disorder in the older person. Geriatr Nurs 1996; 17:75-78
24. Calabrese JR, Woyshville MJ: Lithium therapy: limitations and alternatives in the treatment of bipolar disorders. Ann Clin Psychiatry 1995; 7:103-112
25. Dardennes R, Heim A, Bange F, et al. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders, a meta-analysis. Br J Psychiatry 1995; 166:378-381
26. Solomon DA, Miller IW, Ryan CE, et al: Lithium plus valproate as maintenance polypharmacy for patients with bipolar 1 disorder: a review. J Clin Psychopharmacol 1998; 18:38-49
27. Denicoff KD, Post RM, Leverich GS, et al: Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58:470-478
28. Dubovsky SL, Buzan RD: Novel alternatives and supplements to lithium and anticonvulsants for bipolar affective disorder. J Clin Psychiatry 1997; 58:224-242
29. Allison DB, Mentore JL, Heo M, et al: Meta-analysis of the effects of anti-psychotic medication on weight gain. Am J Psychiatry 1999 (In press)
30. Gardos G, Cole JO: Weight reduction in schizophrenics by molindone. Am J Psychiatry 1977; 134:302-304
31. Doss FW: The effect of antipsychotic drugs on body weight: a retrospective review. J Clin Psychiatry 1979; 40:528-530
32. Baptista T, Alastre T, Contreras Q, et al: Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation. Pharmacopsychiatry 1997; 30:350-355
33. Breum L, Astrup A, Gram L, et al: Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992; 41:666-670
34. Lampl Y, Eshel Y, Rapaport A, et al: Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clin Neuropharmacol 1991; 14:251-255
35. Horber FF, Zurcher RM, Herren H, et al: Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. Am J Clin Nutr 1986; 43:758-769
36. Smith MA, Youngkin EQ: Current perspectives on combination oral contraceptives. Clin Pharmacol 1984; 3:485-496
37. Oelkers W, Foidart JM, Dombrovicz N, et al: Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80:1816-1821
38. PEPI Writing Group: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women, the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273:199-208
39. Kupfer DJ, Coble PA, Rubinstein D: Changes in weight during treatment for depression. Psychosom Med 1979; 41:535-544
40. Andrew R, Phillips DI, Walker BR: Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 1998; 83:1806-1809
41. Beasley CM Jr, Tollefson GD, Tran PV: Safety of olanzapine. J Clin Psychiatry 1997; 58(suppl 10):13-17
42. Curtis JJ, Galla JH, Woodford SY, et al: Comparison of daily and alternate-day prednisone during chronic maintenance therapy: a controlled crossover study. Am J Kidney Dis 1981; 1:166-171
43. Pijl H, Meinders AE: Bodyweight change as an adverse effect of drug treatment: mechanisms and management. Drug Saf 1996; 14:329-342
44. Noyes R, Garvey MJ, Cook BL, et al: Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J Clin Psychiatry 1989; 50:163-169